RU-486: THE ABORTION BATTLE’S NEW FRONTIER : RU-486: A Chronology
1970: Dr. Etienne-Emile Baulieu and his research team discover receptors within uterine cells that interact with the hormone progesterone. They recognize this knowledge might lead to new methods of fertility control.
1980: The Baulieu research team at Roussel-Uclaf, a Paris-based drug company, creates an “anti-hormone” that blocks the progesterone necessary to sustain pregnancy. The steroid is named RU-38486: RU for Roussel-Uclaf and 38486, the number assigned by the firm. It is shortened to RU-486.
1982: Roussel-Uclaf begins clinical tests on women. The drug (used without a prostaglandin booster) averages an effectiveness rate of 80% to 85%. Abortions that fail with the pill are surgically completed.
1983: In the United States, the FDA issues a testing permit on RU-486 to the nonprofit Population Council.
1984: Studies of RU-486 obtained through the Population Council begin in July at L.A. County-USC Medical Center under the direction of Dr. Daniel Mishell. In Sweden, in a study sponsored by the World Health Organization, the effectiveness of RU-486 used in conjunction with a prostaglandin is examined for the first time. In women receiving both RU-486 and a prostaglandin, the abortion effectiveness rate is 94%.
1988: In September, following Roussel-Uclaf trials in which RU-486 produces a success rate of 96%, RU-486 is approved for use in France. In October, Roussel-Uclaf announces it will suspend marketing of RU-486. Two days later, the French minister of health orders RU-486 back on the market. In December, Roussel-Uclaf announces it will suspend distribution of RU-486 outside of France.
1989: In February, Roussel-Uclaf begins widespread distribution of RU-486 to licensed medical clinics and hospitals in France. Women must agree to surgery if a failed abortion results. In September, Baulieu receives America’s prestigious Lasker Award. By October, one year from Roussel-Uclaf’s brief suspension of the drug in France, more than 30,000 women are reported to have used RU-486.
1990: County-USC studies end in mid-February. Efforts to secure more RU-486 are unsuccessful. In March, Roussel-Uclaf announces it is considering marketing RU-486 in Britain, the Netherlands and Scandinavian countries. In March, the New England Journal of Medicine reports on Roussel-Uclaf research concluding that RU-486, coupled with a prostaglandin, is 96% effective--and as safe as suction abortion. In March, the two Democratic candidates for governor of California announce they favor continued United States testing of RU-486.
Get our free Coronavirus Today newsletter
Sign up for the latest news, best stories and what they mean for you, plus answers to your questions.
You may occasionally receive promotional content from the Los Angeles Times.